Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $236.6 million.

  • Madrigal Pharmaceuticals' Cash from Financing Activities rose 307136.16% to $236.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.8 million, marking a year-over-year decrease of 7767.76%. This contributed to the annual value of $735.1 million for FY2024, which is 2351.58% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Cash from Financing Activities of $236.6 million as of Q3 2025, which was up 307136.16% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash from Financing Activities registered a high of $573.7 million during Q1 2024, and its lowest value of $1.7 million during Q2 2025.
  • For the 5-year period, Madrigal Pharmaceuticals' Cash from Financing Activities averaged around $121.3 million, with its median value being $49.1 million (2022).
  • In the last 5 years, Madrigal Pharmaceuticals' Cash from Financing Activities skyrocketed by 5819449.54% in 2021 and then crashed by 9870.19% in 2025.
  • Over the past 5 years, Madrigal Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $19.5 million in 2021, then soared by 1255.37% to $264.3 million in 2022, then soared by 81.55% to $479.9 million in 2023, then plummeted by 95.88% to $19.8 million in 2024, then skyrocketed by 1096.94% to $236.6 million in 2025.
  • Its last three reported values are $236.6 million in Q3 2025, $1.7 million for Q2 2025, and $8.6 million during Q1 2025.